

## Plausible role of combination of Chlorpromazine hydrochloride and Teicoplanin against COVID-19



To the editor


COVID-19 is an endangering viral infection claiming lakhs of lives across the globe. The early spread of COVID-19 was reported from Wuhan, China in December 2019 [1], and was declared as pandemic on March 11, 2020 [2]. COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or generally referred to as Novel coronavirus (2019-nCoV) [3], is posing a serious threat to mankind. However, as the drug development process is very lengthy, to face this alarming global challenge we may need to think of an alternate way. Repurposing the clinical use of an 'old' drug to treat 'new' disease could be an effective strategy to confront the present context of the COVID-19 pandemic [4] (Fig 1.).

Chlorpromazine hydrochloride (CPZ-HCl), an anti-psychotic agent reported to show *in vitro* antiviral activity with a IC 50 of 3.14 Mm [5] by inhibiting assembly and disassembly of Clathrin lattices on cell surfaces and endosomes by CPZ-HCl and thereby prevents the entry of virus into host cells. [6]. Teicoplanin (TCP), a broad spectrum anti-

bacterial drug, reported to show *in vitro* antiviral activity with a IC 50 of 1.66  $\mu$ M [7], by inhibiting low pH cleavage of viral spike protein cathepsin in late endosomes during the early stages of viral life cycle. This averts the release of viral RNA and its further replication [7], which conserved towards COVID-19 [8]. As both these drugs are FDA approved, a combination of these two drugs can be used for COVID-19. Hence, based on the available information on possible mechanisms of actions of CPZ-HCl and TCP, a combination can be suggested for further investigation, to target COVID-19 primarily by inhibiting clathrin mediated endocytosis with CPZ-HCl and secondarily by preventing low pH cleavage of viral spike protein of viral proteins which might have escaped the endocytosis inhibition.

### Funding source

The article has no funding source.



**Fig. 1.** Structure of COVID-19 Virus; Plausible role of combination of Chlorpromazine hydrochloride and Teicoplanin in controlling COVID-19 replication, where Chlorpromazine hydrochloride inhibiting binding of virus to Clathrin pits and Teicoplanin inhibiting low pH cleavage of viral spike protein.

## Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.mehy.2020.110011>.

## References

- [1] Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. *Eurosurveillance* 2020;25:2000058.
- [2] Dikid T, Chaudhary S, Goel K, et al. Responding to COVID-19 pandemic: Why a strong health system is required. *Indian J Med Res* 2020;151:140.
- [3] Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. *International journal of antimicrobial agents*. 2020. p. 105924.
- [4] Harrison C. Coronavirus puts drug repurposing on the fast track. *Nat Biotechnol* 2020;38:379–81.
- [5] Weston S, Haupt R, Logue J, Matthews K, Frieman M. FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro. *bioRxiv* 2020.
- [6] Wang L-H, Rothberg KG, Anderson R. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. *J Cell Biol* 1993;123:1107–17.
- [7] Zhang J, Ma X, Yu F, et al. Teicoplanin potently blocks the cell entry of 2019-nCoV. *bioRxiv* 2020.
- [8] Baron SA, Devaux C, Colson P, Raoult D, Rolain J-M. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19. *Int J Antimicrob Agents* 2020:105944.

NandhaKumar Sathyamoorthy<sup>a</sup>, Pavan Kumar Chintamaneni<sup>b,\*</sup>,  
Santhivardhan Chinni<sup>c</sup>

<sup>a</sup> Department of Pharmaceutics, Faculty of Pharmacy, Dr. M.G.R. Educational and Research Institute, Velappanchavadi, Chennai, Tamil Nadu 600077, India

<sup>b</sup> Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research (RIPER), Anantapuramu, Andhra Pradesh 515721, India

<sup>c</sup> Department of Pharmacology, RERDS-CPR, Raghavendra Institute of Pharmaceutical Education and Research, Anantapuramu, Andhra Pradesh, India

E-mail address: [pavanchintamaneni@gmail.com](mailto:pavanchintamaneni@gmail.com) (P.K. Chintamaneni).

\* Corresponding author at: Department of Pharmaceutics, Raghavendra Institute of Pharmaceutical Education and Research (RIPER)-Autonomous, K.R. Palli Cross, Cheyyedu (Po), Anantapuramu, Andhra Pradesh 515721, India.